10.85

3.33% 0.35

Neumora Therapeutics Inc (NMRA)

Overview News Price History Option Chain Financials Why NMRA Down? Discussions Forecast

Neumora Therapeutics Inc stock is traded at $10.85, with a volume of 1.79M. It is up +3.33% in the last 24 hours and up +10.83% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Previous Close:

$10.50

Open:

$10.17

24h Volume:

1.79M

Relative Volume:

1.57

Market Cap:

$1.75B

Revenue:

Net Income/Loss:

$-274.18M

P/E Ratio:

-6.3147

EPS:

-1.7182

Net Cash Flow:

$-198.33M

1W Performance:

+5.14%

1M Performance:

+10.83%

6M Performance:

+22.60%

1Y Performance:

-25.07%

1-Day Range:

$10.07

$11.10

1-Week Range:

$9.89

$11.16

52-Week Range:

$8.33

$21.00

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name

Neumora Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

(857) 760-0900

Address

490 ARSENAL WAY, SUITE 200, WATERTOWN

Employee

109

Twitter

Next Earnings Date

Latest SEC Filings

NMRA's Discussions on Twitter

Compare NMRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NMRA Neumora Therapeutics Inc	10.85	1.75B	0	-274.18M	-198.33M	-2.5346
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jul-22-24	Initiated	Needham	Buy
Jul-08-24	Initiated	Mizuho	Outperform
Dec-12-23	Initiated	Deutsche Bank	Hold
Oct-10-23	Initiated	BofA Securities	Buy
Oct-10-23	Initiated	Guggenheim	Buy
Oct-10-23	Initiated	JP Morgan	Overweight
Oct-10-23	Initiated	RBC Capital Mkts	Outperform
Oct-10-23	Initiated	Stifel	Buy
Oct-10-23	Initiated	William Blair	Outperform

View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

Dec 20, 2024

Neumora Therapeutics Inc put volume heavy and directionally bearish - TipRanks

Dec 20, 2024

Commit To Buy Neumora Therapeutics At $5, Earn 105.2% Annualized Using Options - Nasdaq

Dec 20, 2024

HC Wainwright Reaffirms “Buy” Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World

Dec 18, 2024

Dec 17, 2024

Neumora Therapeutics (NASDAQ:NMRA) Given Buy Rating at HC Wainwright - Defense World

Dec 17, 2024

Dec 16, 2024

Neumora Therapeutics (NASDAQ:NMRA) Earns Buy Rating from HC Wainwright - MarketBeat

Dec 16, 2024

Neumora shares retain Buy rating ahead of clinical trial results By Investing.com - Investing.com Canada

Dec 16, 2024

Dec 15, 2024

Neumora Therapeutics' SWOT analysis: stock's potential in depression treatment market - Investing.com

Dec 15, 2024

Dec 13, 2024

Stock Traders Purchase High Volume of Neumora Therapeutics Call Options (NASDAQ:NMRA) - Defense World

Dec 13, 2024

Dec 11, 2024

Point72 Asset Management L.P. Takes Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat

Dec 11, 2024

The Manufacturers Life Insurance Company Trims Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

Dec 11, 2024

Dec 10, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Holdings Raised by Charles Schwab Investment Management Inc. - MarketBeat

Dec 10, 2024

Dec 09, 2024

(NMRA) Proactive Strategies - Stock Traders Daily

Dec 09, 2024

Dec 08, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 08, 2024

Dec 07, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by Wexford Capital LP - MarketBeat

Dec 07, 2024

Intech Investment Management LLC Makes New $175,000 Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

Dec 07, 2024

Dec 06, 2024

RBC maintains $29 target on Neumora amid JNJ trial update By Investing.com - Investing.com UK

Dec 06, 2024

Dec 05, 2024

Fmr LLC Trims Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat

Dec 05, 2024

Dec 01, 2024

Cerity Partners LLC Purchases New Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat

Dec 01, 2024

Nov 27, 2024

Head-To-Head Analysis: Neumora Therapeutics (NMRA) vs. Its Competitors - Defense World

Nov 27, 2024

Nov 26, 2024

Neumora Therapeutics' SWOT analysis: stock poised for growth amid MDD trial - Investing.com Canada

Nov 26, 2024

Nov 25, 2024

Neumora Therapeutics’ (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - Defense World

Nov 25, 2024

Nov 23, 2024

Neumora Therapeutics' (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat

Nov 23, 2024

Contrasting Neumora Therapeutics (NMRA) and Its Competitors - Defense World

Nov 23, 2024

Nov 21, 2024

Head-To-Head Survey: Neumora Therapeutics (NMRA) vs. Its Rivals - Defense World

Nov 21, 2024

Nov 20, 2024